Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Open-Label Study of APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma and Immunoglobin Light Chain Amyloidosis

Next Previous
Trial Profile

A Phase Ib/II Open-Label Study of APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma and Immunoglobin Light Chain Amyloidosis

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Lisaftoclax (Primary) ; Pomalidomide (Primary)
  • Indications Amyloidosis; Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Ascentage Pharma

Most Recent Events

  • 10 Dec 2024 According to an Ascentage Pharma media release, company announced that it has released the latest clinical data of this trial , in an Oral Report at the 66th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, CA, the United States.
  • 06 Nov 2024 According to an Ascentage Pharma media release, data from this trial to be presented, at the 66th American Society of Hematology (ASH) Annual Meeting. The 66th ASH Annual Meeting will take place on Dec 7-10, 2024, local time, both online and in-person in San Diego, CA (United States).
  • 18 Jun 2024 According to Ascentage pharma media release, updated data from this study presented at the 2024 European Hematology Association Hybrid Congress (EHA 2024), taking place in Madrid, Spain.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top